دانلود کتاب آنتی بادی-دارو آمیخته شده: اصول، ساخت دارو و پیامدهای بالینی برای هدف سرطان
Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer, 1ed
Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells.
• Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies
• Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging
• Includes case studies of ADCs in oncology drug development
• Features contributions from highly-regarded experts on the frontlines of ADC research and development
From the Back Cover
Antibody-drug conjugates (ADCs) are a type of targeted therapy, used most notably for cancer, and consist of an antibody (or antibody fragment) linked to a payload drug which is often cytotoxic. Because of the targeting, the side effects should be lower and give a wider therapeutic window. By combining the unique targeting of antibodies with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue – leading to widespread enthusiasm in the oncology drug development community.
Providing practical and proven solutions for ADC drug discovery success in oncology, Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. Featuring contributions from highly-regarded experts on the frontlines of ADC research and development, the book covers the basics, chemistry and manufacturing (CMC) controls, nonclinical pharmacology and toxicology, clinical outcomes and regulatory approval strategies, and case studies from oncology drug discovery.
Readers benefit through gaining an improved understanding of ADC fundamentals, strategies for targeted and tailored drug release, computational modelling practices, and insights into optimizing and assessing nonclinical studies and regulatory strategies. In addition, the chapters offer discussion on the conduct and design of oncology clinical trials, using ADCs to image tumors and guide clinical protocol development, and therapeutic regimens.
Considering how expansive the field is and the potential benefit to researchers, clinicians, and – ultimately –patients, this comprehensive book with the newest cutting edge information offers a critical resource and reference for the growth of oncology drug development.
About the Author
Kenneth J. Olivier, Jr., PhD, is Head of Toxicology, Discovery Regulatory, Bioanalytical Assay Development, Pharmacokinetics and Discovery Project Management at Merrimack Pharmaceuticals and has over 13 years’ experience in the biotechnology and pharmaceutical industries.
Sara A. Hurvitz, MD, is an Associate Professor of Medicine at the University of California, Los Angeles (UCLA); Co-Director of the Santa Monica-UCLA Outpatient Oncology Practice; Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Center of UCLA; and Director of the Breast Oncology Program, Division of Hematology-Oncology, at UCLA.
۱ Typical Antibody-Drug Conjugates
۲ Selecting Optimal Antibody-Drug Conjugate Targets Using Indication-Dependent or Indicationlndependent Approaches
۳ Antibody-Drug Conjugates: An Overview of the CMC and Characterization Process
۴ Linker and Conjugation Technology; and Improvements
۵ Formulation and Stability
۶ QC Assay Development
۷ Occupational Health and Safety Aspects of ADCs and Their Toxic Payloads
۸ Bioanalytical Strategies Enabling Successful ADC Translation
۹ Nondinical Pharmacology and Mechanistic Modeling of Antibody-Drug Conjugates in Support of Human Clinical Trials
۱۰ Pharmacokinetics of Antibody-Drug Conjugates
۱۱ Path to Market Approval: Regulatory Perspective of ADC Nondinical Safety Assessments
۱۲ Antibody-Drug Conjugates: Clinical Strategies and Applications
۱۳ Antibody-Drug Conjugates (ADCs) in Clinical Development
۱۴ ADCs Approved for Use: Trastuzumab Emtansine
۱۵ ADCs Approved for Use: Brentuximab Vedotin
۱۷ Radiolabeled Antibody-Based Imaging in Clinical Oncology
۱۸ Next-Generation Antibody-Drug Conjugate Technologies
لینک کوتاه : https://bookbaz.ir/?p=55370
نویسنده : Kenneth J. Olivier Jr. , Sara A. Hurvitz
ناشر : Wiley; 1 edition
سال انتشار : 2017
زبان کتاب : انگلیسی
نوع فایل : PDF
تعداد صفحات : 564
(ISBN) شابک : 1119060680
قیمت کتاب درآمازون : $139.71
حجم فایل : 5 MB